Karuna Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Karuna Therapeutics, Inc.

Karuna Therapeutics, Inc. (ticker KRTX) was a U.S.-based biopharmaceutical company focused on neuroscience and psychiatry. It was listed on the NASDAQ in the United States, and it ceased to operate as a standalone public company after Bristol Myers Squibb completed its acquisition on March 18, 2024. As a result, Karuna is best understood today as a former listed biotech whose legacy centered on the development of differentiated therapies for psychiatric and neurological disorders. Its historic headquarters were in Boston, Massachusetts, at 99 High Street. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1771917/000114036124013927/xslF345X05/form4.xml?utm_source=openai)) Karuna was built around a research platform targeting central nervous system diseases, with a particular emphasis on muscarinic receptor modulation. Its lead asset was KarXT (xanomeline-trospium), an oral, first-in-class or potentially first-in-class antipsychotic program designed for adult schizophrenia, with additional development work in Alzheimer’s disease psychosis and other neuropsychiatric settings. The company’s story was that of a focused clinical-stage innovator rather than a diversified pharmaceutical group: it aimed to create value through a single highly differentiated scientific platform and a small number of high-impact programs. ([nasdaq.com](https://www.nasdaq.com/press-release/bristol-myers-squibb-strengthens-neuroscience-portfolio-with-acquisition-of-karuna?utm_source=openai)) From a competitive standpoint, Karuna occupied a niche at the intersection of psychiatry and neurology, competing indirectly against established antipsychotics and against the broader industry’s search for more effective treatments with improved tolerability. Its competitive edge lay in KarXT’s novel mechanism and the possibility of addressing unmet needs in schizophrenia and related disorders. At the same time, Karuna had the classic risk profile of a clinical-stage biotech: heavy dependence on one lead asset, binary regulatory milestones, and no large-scale commercial franchise to cushion setbacks. ([nasdaq.com](https://www.nasdaq.com/press-release/bristol-myers-squibb-strengthens-neuroscience-portfolio-with-acquisition-of-karuna?utm_source=openai)) Geographically, Karuna’s business was overwhelmingly U.S.-centered, with its research and corporate base in Boston and its initial commercial/regulatory ambition focused on the U.S. market through the FDA. A major recent milestone was the December 22, 2023 announcement that Bristol Myers Squibb would acquire Karuna for $330.00 per share in cash, implying an equity value of about $14.0 billion. The deal closed on March 18, 2024, and Karuna became part of Bristol Myers Squibb’s neuroscience portfolio. For international investors, this means KRTX is now primarily a historical reference point in the U.S. biotech sector rather than an independently traded operating company. ([nasdaq.com](https://www.nasdaq.com/press-release/bristol-myers-squibb-strengthens-neuroscience-portfolio-with-acquisition-of-karuna?utm_source=openai))